Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years
After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
